Scores by kind of claim
Each kind of claim is scored on its own, out of 100: the share that held up, with the range it likely falls in. Fewer resolved claims give a wider range.
-
Factual claims
Statements about the present or the past, checked against the record: did they hold up?
76 70 81 -
Predictions
Statements about events outside the person's control, checked once they fell due: did they come true?
68 54 82 -
Promises
Commitments to the person's or organisation's own future action, with something to deliver: was it delivered?
Insufficient record: 3 promises resolved, 5 needed for a score.
All types combined: 74 (likely 69 to 80, high confidence), from 96 claims: 82 factual claims, 14 predictions. It mixes kinds of claim in different proportions for different people, so compare people kind by kind.
Bill Ackman's claims
42 claims
“First, legacy issues impacted performance including the cost of the Allergan settlement, losses on the exit from Valeant and from our short position in Herbalife.”
Bill Ackman, letter to PSH shareholders 2018 Annual Report Year Ended December 31, 2017 - Letter (Pershing Square Holdings)
In 2017 Pershing Square's performance was hurt by the cost of the Allergan settlement, losses on the exit from Valeant, and losses from its short position in Herbalife.
Mostly true True in substance, wrong in a detail.
The second judge would not resolve this claim; the verdict shown is the first judge's.
Said for an organisation they lead or work for; it counts on both records.
What would count as true or false
The claim has three parts. Each must be checked against Pershing Square Holdings' 2017 annual report or Pershing Square's 2017 investor letters: (1) the cost of the Allergan insider-trading litigation settlement hurt 2017 performance; (2) Pershing Square exited Valeant at a loss in 2017; (3) the Herbalife short lost money in 2017 or on its exit. True: all three are documented as losses or costs that hurt 2017 performance. Mostly true: all three occurred but one is dated slightly differently (for example, the settlement was partly booked in late 2017 or early 2018), or one was immaterial. Mixed: two of the three hold. Mostly false: only one holds. False: none was a loss or cost affecting 2017.
Evidence
- Pershing Square Announces Agreement in Principle to Settle Lawsuits Related to Allergan | Pershing Square Holdings Pershing Square Holdings, Ltd. · 29 December 2017 Own record
“Pershing Square had previously set aside $75 million in legal reserves related to the case. The incremental cost of settling the litigation will reduce PSH’s and the private funds’ performance and net asset value by 132 basis points.”
- Bill Ackman And Valeant Settle Allergan Insider Trading Lawsuit For $290 Million Forbes · 30 December 2017
“The hedge fund with over $9 billion in assets will see its performance dip by a further 1.32% as funds are used to pay down the $193.75 million claim.”
- Bill Ackman And Valeant Settle Allergan Insider Trading Lawsuit For $290 Million Forbes · 30 December 2017
“When Pershing Square sold its shares, Ackman locked in an almost $4 billion loss, one of the biggest in the history of hedge funds.”
- Bill Ackman And Valeant Settle Allergan Insider Trading Lawsuit For $290 Million Forbes · 30 December 2017
“Ackman's hedge fund Pershing Square will pay $193.75 million of the insider trading settlement, far more than the $75 million it had reserved earlier this year, Forbes first reported, while Valeant will fork over $96.25 million.”
- Bill Ackman And Valeant Settle Allergan Insider Trading Lawsuit For $290 Million Forbes · 30 December 2017
“The hedge fund with over $9 billion in assets will see its performance dip by a further 1.32% as funds are used to pay down the $193.75 million claim.”
- Bill Ackman And Valeant Settle Allergan Insider Trading Lawsuit For $290 Million Forbes · 30 December 2017
“When Pershing Square sold its shares, Ackman locked in an almost $4 billion loss, one of the biggest in the history of hedge funds.”
- [PDF] Pershing Square Announces Agreement in Principle to Settle ... - AFM Autoriteit Financiële Markten (AFM), hosting Pershing Square Holdings' release · 29 December 2017 Own record
“The incremental cost of settling the litigation will reduce PSH's and the private funds' performance and net asset value by 132 basis points.”
- Ackman Sells Entire Valeant Stake, Takes Huge Loss - Law360 Law360 · 14 March 2017
“have sold their entire stake in the embattled drug company Valeant Pharmaceuticals International Inc. at a $3 billion-plus loss”
- Pershing Square Capital Management, L.P. Announces Sale of Its Investment In Valeant Pharmaceuticals International, Inc. | Pershing Square Holdings Pershing Square Holdings, Ltd. · 13 March 2017 Own record
“As a result, we elected to sell our investment and realize a large tax loss which will enable us to dedicate more time to our other portfolio companies and new investment opportunities.”
- Pershing Square 1Q17 Shareholder Letter May 11 2017 PSH Scribd (copy of Pershing Square 1Q17 shareholder letter) · 11 May 2017 Own record
“Despite weak financial performance in Q1, Herbalifes share price has appreciated by more than 50% year-to-date.”
Reasoning
Pershing Square's 29 December 2017 announcement and Forbes coverage say the extra cost of the Allergan settlement would cut 2017 performance and NAV by 132 basis points (E2, E3, E5, E9). Law360 and Pershing Square's own release show the fund sold its entire Valeant stake in March 2017 at a loss of more than $3 billion (E10, E11, E4). For Herbalife, the first-quarter 2017 letter says the share price had risen more than 50% that year, which implies losses on the short (E12). However, no source documents the full-year 2017 result of the Herbalife short; the 1Q17 letter shows only that Herbalife's share price rose more than 50% year-to-date by May 2017, which is adverse for a short [E12], so that part is only partly shown.
Cite this claim
Bill Ackman, “In 2017 Pershing Square's performance was hurt by the cost of the Allergan settlement, losses on the exit from Valeant, and losses from its short position in Herbalife.” (said 2018). Verdict: mostly true. Reliability API, claim c_710740634fa4, method 0.1.0+c876030c. https://epistacklabs.com/claims/c_710740634fa4
Claims without a verdict
- Unresolvable 135
- Not yet due 9
- Own records only 29
- Not researched 162
- Not checkable 431
Is a verdict here wrong, or do you speak for Bill Ackman? Reply on the claim's own page, with the form at its foot (how replies work). Verdicts are made automatically; how verdicts and scores are made.